Navigation Links
Researchers gain ground in efforts to fight parasite infection
Date:5/26/2009

DALLAS May 26, 2009 New findings by researchers UT Southwestern Medical Center are accelerating efforts to eradicate worm infections that afflict a third of the world's population.

The new findings, available online and in an upcoming issue of the Proceedings of the National Academy of Sciences, demonstrate that a biochemical system that controls development and reproduction of Caenorhabditis elegans, a common research worm, also provides the same function in several parasitic nematodes, including hookworm.

In these parasitic organisms, the activating molecule, called dafachronic acid, sends the necessary signals for the worms to mature from the stage in which they infect a host to the stage in which they start feeding on the host, which is what makes the host sick. In 2006 UT Southwestern scientists led by Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern and senior author of the new study in PNAS, had made the discovery in C elegans, a nematode about the size of a pinhead.

In the new study, the UT Southwestern researchers treated hookworm parasites pharmacologically at the infective larval stage with dafachronic acid, causing them to pass into the "feeding" larval stage outside a host, where they had no food supply and died. Treatment of other infectious species had similar effects.

"We essentially coaxed them to mature before a food source the host is available," Dr. Mangelsdorf said.

Many infectious nematode larva live in the soil, often in areas where proper sanitation is lacking. According to the World Health Organization, parasitic nematodes infect about 2 billion people worldwide and severely sicken some 300 million, at least 50 percent of whom are school-age children.

The results point to a promising therapeutic target for the infectious nematodes, said Dr. Mangelsdorf, an investigator with the Howard Hughes Medical Institute at UT Southwestern.

"What keeps these parasites infectious is the lack of production of dafachronic acid," he said. "Once they get inside the host, however, something switches them on to begin making this compound. We can interrupt the worm's life cycle just by giving it this compound when it's in the infectious state, before it enters a host."

The nature of that switch is still under investigation. It may be that the parasite itself somehow senses it is inside the host and begins making the compound, or the parasite could receive a signal from the host to begin production, Dr. Mangelsdorf said. There also is the possibility that the parasite receives the dafachronic acid, or its precursor building blocks, from the host, he said.

Whatever the source of dafachronic acid, the researchers are confident that the compound is worth pursuing as a possible therapeutic target. In the study, the researchers present additional details about the nature of different forms of dafachronic acid and how they function in specific nematodes.

Dr. Mangelsdorf said the next step in the research is to screen large libraries of chemicals to search for compounds that behave like dafachronic acid and that could possibly be developed into pesticides that could be spread in high-infection areas.


'/>"/>

Contact: Amanda Siegfried
amanda.siegfried@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Poor attention in kindergarten predicts lower high school test scores, UC Davis researchers find
2. NYU School of Medicine pathology researchers solve another mystery in B lymphocyte development
3. Mayo Clinic Researchers Examine the Psychological Impact of Child Abuse
4. Mayo Clinic researchers examine the psychological impact of child abuse
5. CSI: Mayo Clinic Researchers Find Television Shows Inaccurately Portray Violent Crime
6. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
7. Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
8. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
9. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
10. BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units
11. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers gain ground in efforts to fight parasite infection
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... ... Magdalene: Grace is Greater than Sin”: a unique and memorable piece of literature ... Grace is Greater than Sin” is the creation of published author, Brenda Roberts, a ... had little knowledge of the female characters portrayed in the Holy Bible. , ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story ... Sara Seymour, who lives in Lafayette, Indiana where she works in a daycare and ... and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare ... four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs ... are an important part of the Administration’s effort to build a system that delivers ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
Breaking Medicine Technology: